Terminated NA INTERVENTIONAL 3-arm NCT00564018

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Sponsor: Novo Nordisk A/S

Interventions Glargine Insulin detemir NPH

Updated 8 times since 2017 Last updated: Oct 10, 2019 Started: Sep 30, 2006 Primary completion: Feb 28, 2009 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Presumed loss of clinical equipoise between the agents being investigated

Other terminated trials from Novo Nordisk A/S

See all terminations from Novo Nordisk A/S

Other Type 1 Diabetes trials with similar outcome

Browse all Type 1 Diabetes trials

This NA trial investigates Type 1 Diabetes and is currently terminated or withdrawn. Novo Nordisk A/S leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Dec 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Dec 2021 [monthly]

Terminated NA
Nov 2019 — Jan 2021 [monthly]

Terminated NA

▶ Show 3 earlier versions

Jun 2018 — Nov 2019 [monthly]

Terminated NA
Feb 2017 — Jun 2018 [monthly]

Terminated NA
Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S
University of Texas Southwestern Medical Center

Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States